Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort | Zendy

Christoph Höner zu Siederdissen | Zendy; Benjamin Maasoumy | Zendy; Fiona Marra | Zendy; Katja Deterding | Zendy; Kerstin Port | Zendy; Michael P. Manns | Zendy; Markus Cornberg | Zendy; David Back | Zendy; Heiner Wedemeyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort

Author(s) -

Christoph Höner zu Siederdissen,

Benjamin Maasoumy,

Fiona Marra,

Katja Deterding,

Kerstin Port,

Michael P. Manns,

Markus Cornberg,

David Back,

Heiner Wedemeyer

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ973

Subject(s) - ombitasvir , sofosbuvir , medicine , dasabuvir , daclatasvir , paritaprevir , ledipasvir , simeprevir , ritonavir , regimen , ribavirin , pharmacology , virology , hepatitis c virus , viral load , virus , antiretroviral therapy

With the approval of direct-acting antivirals (DAAs), the management of drug-drug interactions (DDIs) has become an important challenge while treating individuals with hepatitis C. To date, the potential of causing DDIs for the recently approved DAAs has not been systematically investigated. We aimed to assess the clinical significance of DDI between the regular outpatient medications and DAA therapies in a large real-world cohort.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research